New biotech startup Strominnate Therapeutics is founded by researcher Tania Ramos Moreno, aiming to treat diseases in the nervous system. Their main focus is a new drug product for treating glioblastoma multiforme, the most deadly brain tumor in adults with only palliative care available.
Strominnate Therapeutics drug candidate is derived from a recently discovered human immune cell and exhibits antitumoral and tissue modulatory properties. In preclinical models, it has been shown to delay tumor progression and extend survival time, and – importantly – modulate the tumor tissue to respond efficiently to immunotherapy.
Strominnate Therapeutics hopes to make immunotherapy effective in therapy-resistant patients.
Strominnate Therapeutics website
Effective treatments for tumors and conditions of the nervous system.
Founded by Tania Ramos-Moreno.
Portfolio company since 2021.
LU Holding Portfolio Manager:
eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie Thordarson), phone +46 46 222 15 59